List of Excipients in Branded Drug LETROZOLE

« Back to Dashboard

Generic Drugs Containing LETROZOLE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	letrozole	0093-7620	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	letrozole	0093-7620	FD&C BLUE NO. 2
Teva Pharmaceuticals USA Inc	letrozole	0093-7620	FD&C YELLOW NO. 5
Teva Pharmaceuticals USA Inc	letrozole	0093-7620	FERRIC OXIDE YELLOW
Teva Pharmaceuticals USA Inc	letrozole	0093-7620	INDIGOTINDISULFONATE SODIUM
Teva Pharmaceuticals USA Inc	letrozole	0093-7620	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in LETROZOLE?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
1	ANHYDROUS LACTOSE
24	CELLULOSE, MICROCRYSTALLINE
1	CI 77492
2	CI 77891
2	CROSCARMELLOSE SODIUM

Letrozole Excipient Strategy and Commercial Opportunities: Formulation, Patent, Regulatory, and Market Analysis

Last updated: October 4, 2026

Letrozole is a mature, off-patent aromatase inhibitor marketed primarily as a 2.5 mg immediate-release tablet. The commercial opportunity is no longer based on basic active-ingredient exclusivity. It is concentrated in low-cost, reliable tablet manufacturing; improved dissolution and bioavailability; patient-friendly dosage forms; global contract development and manufacturing; and differentiated formulations for fertility, oncology, and underserved markets.

The most attractive excipient strategy addresses letrozole’s low dose, poor aqueous solubility, content-uniformity risk, tablet manufacturability, and long-term stability. Standard immediate-release tablets remain the lowest-risk regulatory product. Solubility-enhanced, orally disintegrating, dispersible, pediatric, and combination products offer greater differentiation but carry higher development and regulatory risk.

What is letrozole and how is it commercially used?

Letrozole is a nonsteroidal aromatase inhibitor that suppresses estrogen synthesis. The reference product is Femara, originally developed and commercialized by Novartis.

Attribute	Letrozole
Active ingredient	Letrozole
Common strength	2.5 mg tablet
Therapeutic class	Aromatase inhibitor
Main approved use	Adjuvant treatment and treatment of advanced breast cancer in postmenopausal women
Common off-label use	Ovulation induction in infertility treatment
Reference product	Femara
Reference sponsor	Novartis
FDA dosage form	Immediate-release tablet
Molecular formula	C17H11N5
Molecular weight	Approximately 285.31 g/mol
Administration	Oral
Generic status	Multiple approved generic products
Biosimilar relevance	None; letrozole is a synthetic small molecule

The FDA approved Femara in 1997 for advanced breast cancer and later expanded its use to adjuvant treatment. Letrozole is also widely used off label for ovulation induction, although fertility use does not create a separate biologic or biosimilar market.

When did letrozole lose exclusivity?

Letrozole lost practical U.S. market exclusivity after expiration of the principal patent estate and the launch of generic products. Generic letrozole tablets have been available in the United States since the mid-2000s.

The principal commercial conclusion is straightforward: a new letrozole product generally cannot rely on composition-of-matter exclusivity. Any remaining patent value is more likely to arise from a specific formulation, manufacturing process, delivery system, combination, or method of use.

Exclusivity category	Letrozole status
Composition-of-matter exclusivity	Expired
Reference-product exclusivity	Expired
Standard 2.5 mg tablet market	Generic competition
Biosimilar exclusivity	Not applicable
Current innovation opportunity	Formulation, delivery, combination, manufacturing, and market access

The FDA Orange Book lists Femara and approved generic letrozole products under the relevant abbreviated new drug application framework. Current patent and exclusivity entries should be checked against the FDA’s live Orange Book database because listing status can change through delisting, expiration, or administrative updates (U.S. Food and Drug Administration [FDA], n.d.-a).

What patents protect letrozole products?

The original letrozole patent estate no longer blocks standard generic tablets in the United States. A developer should separate three categories of intellectual property:

1. Expired active-ingredient patents.
2. Expired or nonblocking reference-product patents.
3. Potentially enforceable later patents covering formulation, process, combination therapy, or a particular patient population.

For standard letrozole tablets, the key commercial risk is usually not infringement of the original drug patent. It is the possibility that a differentiated formulation could read on a later patent owned by a formulation developer, excipient supplier, or specialty pharmaceutical company.

What formulation patents could cover letrozole?

Potential claim categories include:

• Solubility-enhanced compositions.
• Solid dispersions and amorphous letrozole.
• Nanoparticle or nanosuspension systems.
• Orodispersible and orally disintegrating tablets.
• Buccal, sublingual, or transmucosal systems.
• Modified-release products.
• Fixed-dose combinations.
• Fertility-specific dosage regimens.
• Process controls that produce a defined polymorph or particle-size distribution.
• Stability-enhanced compositions with specified impurity limits.
• Pediatric liquid or multiparticulate formulations.

A formulation patent is more defensible when it combines a defined physical form with measurable performance, such as dissolution, particle-size distribution, impurity profile, stability, or pharmacokinetic improvement. Broad claims that merely list conventional excipients are more vulnerable to obviousness and enablement challenges.

What is the Orange Book status of letrozole?

Letrozole is an FDA-approved small-molecule product with generic competition. The Orange Book is relevant for NDA and ANDA products, patent listings, therapeutic equivalence codes, and reference-product designations. It is not a biosimilar reference product.

For a new 2.5 mg tablet, the principal regulatory route is an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference product. A new formulation that changes the dosage form, release profile, route of administration, or clinical performance may require a different FDA pathway, including a 505(b)(2) application.

Product concept	Likely U.S. pathway	Main evidence burden
Conventional 2.5 mg immediate-release tablet	ANDA	Pharmaceutical equivalence, bioequivalence, CMC
Different excipient system with same dosage form	ANDA if eligible	Equivalence, formulation and manufacturing controls
Orally disintegrating tablet	Potential ANDA or 505(b)(2)	Product-specific equivalence and performance data
New modified-release product	505(b)(2) likely	Comparative pharmacokinetics and possible clinical data
Pediatric liquid	505(b)(2) or other applicable pathway	Stability, dosing accuracy, palatability, safety
Fixed-dose combination	505(b)(2) or NDA pathway	Combination justification and clinical evidence
Fertility-specific product	Potential 505(b)(2)	Labeling, pharmacology, and clinical support

Which excipients are suitable for a conventional letrozole tablet?

A conventional immediate-release tablet should prioritize content uniformity, low manufacturing cost, robust compression, fast disintegration, acceptable dissolution, and chemical stability.

Because the target dose is only 2.5 mg, letrozole represents a low-dose formulation problem. Small variations in blending, segregation, or powder transfer can create large percentage differences in active content. The formulation should therefore use a controlled premix or ordered-mixture approach rather than relying on casual geometric dilution.

Core excipient functions

Formulation function	Candidate excipients	Commercial rationale
Diluent	Microcrystalline cellulose, lactose monohydrate, mannitol, dibasic calcium phosphate	Controls tablet weight and improves manufacturability
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Supports granule strength and tablet integrity
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Wetting agent	Poloxamer, sodium lauryl sulfate, selected surfactants	Can improve dissolution of poorly wetting drug
Film former	Hypromellose, polyvinyl alcohol	Improves handling, appearance, and swallowability
Opacifier	Titanium dioxide or approved alternatives, depending on jurisdiction	Supports light protection and appearance
Colorant	Iron oxides or jurisdictionally permitted colors	Product identification and branding

A lactose-microcrystalline cellulose system is a practical starting point for immediate-release tablets. Mannitol can support a premium mouthfeel and is useful in orally disintegrating products, but it generally increases cost. Dibasic calcium phosphate can improve compactibility and density, although it may complicate dissolution and compatibility optimization.

Magnesium stearate should be tightly controlled. Excessive concentration or over-lubrication can reduce tablet tensile strength and slow dissolution. Sodium stearyl fumarate can be evaluated where a less hydrophobic lubricant profile is commercially useful.

How should excipients address letrozole’s solubility?

Letrozole has limited aqueous solubility. Solubility and wetting should be assessed early because a tablet can meet mechanical specifications while underperforming in dissolution.

A conventional formulation may use particle-size reduction, a wetting agent, a high-surface-area carrier, or a disintegrant system. More complex approaches can create stronger differentiation.

Tiered solubility strategy

Development tier	Approach	Value	Risk
Tier 1	Micronized active ingredient and optimized disintegration	Low cost	Moderate improvement
Tier 2	Surfactant-assisted wetting and porous excipient system	Moderate cost	Compatibility and regulatory control
Tier 3	Solid dispersion using polymeric carrier	Higher differentiation	Physical stability and scale-up
Tier 4	Nanocrystal or nanosuspension technology	Strong performance potential	Manufacturing and characterization burden
Tier 5	Co-crystal, salt, or novel solid form	Potentially strong IP	Solid-state, CMC, and patent risk

Polyvinylpyrrolidone, copovidone, hydroxypropyl cellulose, and hypromellose acetate succinate can be evaluated as polymeric carriers in a solid-dispersion program. The selection should be based on drug-polymer miscibility, moisture sensitivity, glass-transition behavior, dissolution performance, and storage stability.

A solid dispersion is commercially attractive only if the performance advantage survives scale-up and long-term storage. Amorphous systems can recrystallize, particularly under elevated humidity. A formulation that depends on an unstable amorphous state may generate more manufacturing risk than commercial value.

What excipient strategy is best for low-dose content uniformity?

Content uniformity is one of the most important technical issues in a 2.5 mg letrozole product. A manufacturer can reduce risk through:

• Controlled particle-size distribution.
• Preblending letrozole with a portion of the diluent.
• Ordered mixing with porous carriers.
• Low-shear blending followed by validated lubrication.
• Granulation where direct compression produces segregation.
• In-process blend uniformity testing.
• Narrow control of bulk density and flow.
• Automated weight control and tablet inspection.
• Validation of hopper residence time and feeder performance.

Direct compression offers the lowest manufacturing cost and shortest process, but it requires excellent powder flow and segregation control. Roller compaction can improve flow and reduce liquid exposure. Wet granulation may improve uniformity and compressibility, but it adds drying, residual-moisture, and process-control requirements.

For a high-volume generic, the preferred commercial design is usually a simple direct-compression or dry-granulation platform using widely available excipients. For a premium formulation, the value must come from better dissolution, reduced variability, easier administration, or a defensible patent position.

What formulations are protected or commercially differentiated?

Conventional immediate-release tablets

This is the largest and most competitive segment. Differentiation depends on cost, supply reliability, packaging, global registration, and contract manufacturing efficiency. Excipients should be inexpensive, globally available, and compatible with common tablet presses.

Orally disintegrating tablets

An orally disintegrating letrozole tablet could target patients with swallowing difficulty and fertility patients seeking simplified administration. Mannitol, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and specialized co-processed excipients are relevant.

Key development metrics include:

• Disintegration time.
• Mechanical strength.
• Friability.
• Mouthfeel.
• Moisture uptake.
• Packaging protection.
• Dose uniformity.
• Dissolution after disintegration.

A fast-disintegrating product does not automatically provide faster systemic exposure. Any pharmacokinetic claim requires comparative data.

Oral liquid or multiparticulate products

A liquid could address pediatric or dysphagia populations, but letrozole’s poor water solubility creates a substantial formulation burden. Suspensions require particle-size control, sedimentation management, redispersibility, preservative strategy, and accurate dosing. A powder-for-reconstitution product can improve shelf life but shifts risk to reconstitution performance and caregiver handling.

Multiparticulates can improve dose flexibility and support capsule, sachet, or sprinkle administration. They also create more complex manufacturing and bioequivalence questions.

Modified-release products

Modified release has limited obvious clinical value because letrozole is already administered at a low daily dose and the reference product is immediate release. A modified-release product would need a clear adherence, tolerability, pharmacokinetic, or clinical benefit to justify its development cost.

Fixed-dose combinations

Potential combinations include endocrine therapy products paired with agents used in breast cancer management or fertility protocols. Commercial value depends on clinical practice, dosing compatibility, treatment duration, and reimbursement. Combination products face greater regulatory and intellectual-property complexity than single-agent generics.

What generic entry risks exist for letrozole?

The market has low entry risk for conventional tablets but higher risk for differentiated products.

Risk area	Conventional tablet	Novel formulation
Active-ingredient patent blocking	Low	Low to moderate
Formulation patent risk	Low	Moderate to high
Bioequivalence risk	Moderate	High
Excipient supply risk	Low	Moderate
Scale-up risk	Low to moderate	High
Pricing pressure	High	Moderate
Regulatory complexity	Low	Moderate to high
Differentiation potential	Low	Moderate to high

Paragraph IV challenges are relevant only if an applicant seeks approval while a listed patent remains active. For a standard generic letrozole tablet, the historic patent barriers have largely fallen away. A new formulation applicant should conduct a current Orange Book review and a broader patent search covering later patents that may not be listed against the reference product.

A formulation patent can affect market entry even when the active ingredient itself is unpatented. Freedom-to-operate analysis should include U.S., European, Japanese, Chinese, Indian, and other target-market filings.

How strong is the letrozole patent estate?

The core letrozole estate is commercially weak for standard tablets because the basic product is long genericized. The strategic patent opportunity lies in a narrowly defined improvement.

IP category	Relative strength for standard letrozole
Original chemical compound	Low
Standard tablet composition	Low
Novel solid form	Moderate
Solubility-enhanced formulation	Moderate to high if data-supported
Orally disintegrating formulation	Moderate
Manufacturing process	Moderate if difficult to design around
Combination product	Moderate to high
New clinical use	Depends on statutory and prior-art landscape
Packaging or device claims	Low to moderate

Patent strength increases when the claimed formulation produces an unexpected result, such as a substantial dissolution improvement, reduced exposure variability, better stability, or a meaningful pharmacokinetic advantage. Claims limited to routine excipient substitutions are less likely to support durable exclusivity.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can participate in the letrozole market through platform technologies rather than through the active ingredient.

High-probability opportunities

• Co-processed direct-compression excipients for low-dose uniformity.
• Low-moisture excipient systems for stability-sensitive formulations.
• Fast-disintegrating platforms for orally disintegrating tablets.
• Solubilizing excipient systems for poorly soluble letrozole.
• Polymer carriers for solid dispersions.
• High-performance lubricants that preserve dissolution.
• Moisture-barrier coating systems.
• Taste-masking systems for oral liquids or dispersible products.
• Continuous-manufacturing excipient blends.
• Excipient premixes designed for global regulatory acceptance.

The strongest near-term market is conventional tablet manufacturing, where buyers prioritize price, supply continuity, compendial status, and reproducible performance. The highest-margin opportunity is a validated solubility-enhancing or orally disintegrating platform supported by comparative data.

Which companies are positioned to compete?

The competitive field includes:

• Originator and reference-product companies.
• Large generic manufacturers.
• Regional generic manufacturers.
• Contract development and manufacturing organizations.
• Excipient suppliers.
• Specialty companies developing fertility or oncology delivery systems.

For standard tablets, competition is primarily manufacturing-driven. Buyers compare landed cost, regulatory history, shortage performance, batch release reliability, and geographic supply. For novel formulations, the relevant competitors are companies with formulation patents, drug-delivery platforms, clinical development capability, and regulatory experience.

Licensing opportunities are more likely to involve a formulation platform, regional commercialization rights, contract manufacturing, or a fixed-dose combination than the basic letrozole molecule. A licensor should demand evidence of dissolution superiority, stability, scale-up readiness, patent scope, and a credible regulatory pathway.

What FDA regulatory issues affect excipient selection?

FDA review of an excipient strategy focuses on safety, quality, functionality, and reproducibility. The formulation should use excipients with established compendial status or a clear regulatory basis. Novel excipients increase development cost and may require additional toxicology and regulatory justification.

Critical CMC elements include:

• Excipient identity and grade.
• Supplier qualification.
• Compendial compliance.
• Residual solvents and elemental impurities.
• Microbial limits.
• Moisture and water activity.
• Compatibility with letrozole.
• Extractables and leachables for relevant packaging.
• Process validation.
• Stability-indicating analytical methods.
• Dissolution method discrimination.

For global products, excipient selection should account for differences among USP-NF, Ph. Eur., JP, and other pharmacopeial standards. Titanium dioxide restrictions and colorant requirements may also affect European and other international products.

How does letrozole compare with competing aromatase inhibitors?

Letrozole competes primarily with anastrozole and exemestane. All are mature oral products, but their formulation and patent opportunities differ.

Product	Class	Common strength	Dosage-form opportunity	Commercial patent position
Letrozole	Nonsteroidal aromatase inhibitor	2.5 mg	ODT, dispersible, solubility enhancement	Mature generic market
Anastrozole	Nonsteroidal aromatase inhibitor	1 mg	Low-dose uniformity and ODT	Mature generic market
Exemestane	Steroidal aromatase inhibitor	25 mg	Solubility and food-effect optimization	Mature generic market

Letrozole’s low dose creates a more pronounced content-uniformity challenge than exemestane’s 25 mg dose. Its poor solubility supports a stronger rationale for dissolution-focused formulation work. Anastrozole is a closer formulation comparator because it is also a low-dose oral aromatase inhibitor.

What revenue exposure and launch scenarios apply?

Revenue potential depends on the product type.

Launch scenario	Expected commercial profile
Commodity 2.5 mg generic tablet	High volume, low margin, significant price competition
Multi-country generic portfolio	Moderate volume, improved scale and supply leverage
ODT or dispersible tablet	Moderate volume, potential price premium
Solubility-enhanced formulation	Lower volume, higher development and IP value
Fertility-focused product	Niche volume, strong adherence and convenience positioning
Pediatric liquid or flexible-dose product	Small market, potentially limited competition
Fixed-dose combination	Higher strategic value, higher clinical and regulatory burden
Excipient platform licensing	Recurring technology revenue if adopted across products

A generic tablet launch typically competes on cost and availability. A differentiated product needs a documented clinical or operational benefit. Without superior performance, the market is likely to treat the product as another substitutable generic.

Key Takeaways

• Letrozole is a mature, genericized small-molecule product with no biosimilar pathway.
• Standard 2.5 mg tablets are the lowest-risk commercial opportunity but face intense price competition.
• The central formulation challenge is low-dose content uniformity combined with limited aqueous solubility.
• Microcrystalline cellulose, lactose, mannitol, croscarmellose sodium, crospovidone, povidone, colloidal silicon dioxide, and controlled lubrication are practical starting points.
• Solubility-enhanced, orally disintegrating, multiparticulate, and flexible-dose products offer greater differentiation.
• Formulation patents, solid-state patents, process patents, and combination patents matter more than the expired original compound estate.
• A conventional product is generally suited to the ANDA pathway; materially different delivery systems may require a 505(b)(2) strategy.
• Excipient suppliers have the strongest opportunities in co-processed direct-compression systems, dissolution-enhancing platforms, and fast-disintegrating technologies.
• The most defensible commercial position combines measurable performance improvement, scalable manufacturing, global excipient acceptability, and a narrow but enforceable patent claim.

FAQs

Can letrozole be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet can use mannitol, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and specialized co-processed excipients. The product must meet dose-uniformity, mechanical, disintegration, dissolution, moisture, and stability requirements.

Is letrozole suitable for a liquid oral formulation?

It can be developed as a suspension or other liquid system, but poor water solubility increases the need for particle-size control, wetting, suspension stability, preservative control, accurate dosing, and packaging studies.

Does letrozole have biosimilar competition?

No. Biosimilars apply to biological products. Letrozole is a chemically synthesized small molecule and competes through generic drug applications.

Can a new letrozole formulation receive patent protection?

Yes, if the formulation contains patentable subject matter such as a novel solid form, defined particle-size distribution, solubility-enhancing composition, delivery system, manufacturing process, or combination. Routine excipient substitution alone may provide weak protection.

Is the main opportunity in letrozole the drug or the excipient platform?

For standard products, the active ingredient is a commodity. The stronger opportunity is a formulation or excipient platform that improves dissolution, content uniformity, administration, stability, or manufacturing economics.

References

1. U.S. Food and Drug Administration. (n.d.-a). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2018). M9 biopharmaceutics classification system-based biowaivers: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m9-biopharmaceutics-classification-system-based-biowaivers

4. National Center for Biotechnology Information. (n.d.). Letrozole. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Letrozole

5. Novartis Pharmaceuticals Corporation. (2011). Femara (letrozole) tablets prescribing information. U.S. Food and Drug Administration.

6. U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/waiver-vivo-bioavailability-and-bioequivalence-studies-immediate-release-solid-oral-dosage-forms-vesm